기면증 치료제 시장 규모, 점유율 및 성장 분석 : 약제 클래스별, 유통경로별, 기면증 유형별, 지역별 - 업계 예측(2026-2033년)

Global Narcolepsy Therapeutics Market size was valued at USD 2.52 Billion in 2024 and is poised to grow from USD 2.75 Billion in 2025 to USD 5.52 Billion by 2033, growing at a CAGR of 9.12% during the forecast period (2026-2033).

The global narcolepsy therapeutics market is driven by increased clinical awareness and the emergence of targeted pharmacological solutions addressing unmet needs. Narcolepsy, a chronic central nervous system disorder, significantly affects productivity, safety, and quality of life. Traditional treatments, primarily stimulants and modafinil, have evolved to include newer agents like pitolisant and solriamfetol, enhancing treatment diversity and encouraging broader adoption among clinicians. This evolving landscape, coupled with improved diagnostic procedures and regulatory support, fuels market expansion while facilitating investment and uptake. Additionally, AI innovations in drug discovery are transforming target identification and patient enrollment, utilizing machine learning to optimize development processes. Collaborative efforts between biotech companies and pharmaceutical firms further streamline research, enabling more efficient therapeutic advancements in this field.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Narcolepsy Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Narcolepsy Therapeutics Market Segments Analysis

Global narcolepsy therapeutics market is segmented by drug class, distribution, narcolepsy type and region. Based on drug class, the market is segmented into Central Nervous System (CNS) Stimulants, Sodium Oxybate (Xyrem), Orexin Receptor Agonists, Pitolisant (Wakix) and Solriamfetol (Sunosi). Based on distribution, the market is segmented into Hospital Pharmacies, Specialty Pharmacies and Online. Based on narcolepsy type, the market is segmented into Narcolepsy Type 1 (with Cataplexy) and Narcolepsy Type 2. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Narcolepsy Therapeutics Market

One key market driver for the global narcolepsy therapeutics market is the increasing prevalence of narcolepsy and heightened awareness about this neurological disorder. As more individuals seek medical attention for sleep-related issues, healthcare providers are expanding their diagnostic capabilities, leading to earlier and more accurate diagnoses of narcolepsy. Additionally, growing public and professional understanding of the condition has significantly reduced stigma, encouraging patients to pursue treatment. The advancement of novel therapies and medications designed to enhance wakefulness and address associated symptoms is further catalyzing market growth, as patients and healthcare systems alike prioritize effective treatment approaches for improved quality of life.

Restraints in the Global Narcolepsy Therapeutics Market

One of the key market restraints for the global narcolepsy therapeutics market is the stringent regulatory approval processes faced by pharmaceutical companies. The comprehensive and often lengthy evaluation required to establish the safety and efficacy of narcolepsy treatments can delay the introduction of new therapies. Additionally, the complexity of narcolepsy itself, coupled with its varied symptoms, complicates the development of universally effective medications, hindering innovation. Furthermore, the limited awareness and understanding of narcolepsy among healthcare providers and patients can lead to underdiagnosis and undertreatment, which ultimately diminishes the market's growth potential and reduces the driving demand for new therapeutic options.

Market Trends of the Global Narcolepsy Therapeutics Market

The Global Narcolepsy Therapeutics market is witnessing a significant shift towards personalized therapy adoption, leading to tailored treatment regimens that consider individual patient characteristics, including phenotypes and comorbid conditions. This trend emphasizes the importance of using emerging biomarker insights to inform dosing strategies and combination therapies aimed at optimizing both daytime symptom management and overall quality of life. As pharmaceutical companies and healthcare providers collaborate to identify distinct patient populations for targeted interventions, there is a growing push from payers and advocacy organizations toward outcomes-focused care models. This evolving landscape fosters the development of differentiated therapeutics and enhances long-term patient adherence and satisfaction.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Narcolepsy Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Central Nervous System (CNS) Stimulants
• Sodium Oxybate (Xyrem)
• Orexin Receptor Agonists
• Pitolisant (Wakix)
• Solriamfetol (Sunosi)

Global Narcolepsy Therapeutics Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Online

Global Narcolepsy Therapeutics Market Size by Narcolepsy Type & CAGR (2026-2033)

• Market Overview
• Narcolepsy Type 1 (with Cataplexy)
• Narcolepsy Type 2

Global Narcolepsy Therapeutics Market Size & CAGR (2026-2033)

• North America (Drug Class, Distribution, Narcolepsy Type)
  • US
  • Canada
• Europe (Drug Class, Distribution, Narcolepsy Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Distribution, Narcolepsy Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Distribution, Narcolepsy Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Distribution, Narcolepsy Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Jazz Pharmaceuticals (Xyrem, Xywav)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axsome Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Harmony Biosciences (Wakix US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioprojet Pharma (Wakix EU)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avadel Pharmaceuticals (Lumryz)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nuvation Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tonix Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalyst Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ligand Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Flamel Technologies (Avadel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerial BioPharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nalpropion Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sunrise Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Balance Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurovance Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations